Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).

Elkind NB, Szentpétery Z, Apáti A, Ozvegy-Laczka C, Várady G, Ujhelly O, Szabó K, Homolya L, Váradi A, Buday L, Kéri G, Német K, Sarkadi B.

Cancer Res. 2005 Mar 1;65(5):1770-7.

2.

Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.

Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S.

Cancer Res. 2005 Feb 15;65(4):1541-6.

3.

Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.

Lopez JP, Wang-Rodriguez J, Chang C, Chen JS, Pardo FS, Aguilera J, Ongkeko WM.

Arch Otolaryngol Head Neck Surg. 2007 Oct;133(10):1022-7.

PMID:
17938326
4.

Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.

Pick A, Wiese M.

ChemMedChem. 2012 Apr;7(4):650-62. doi: 10.1002/cmdc.201100543. Epub 2012 Feb 22.

PMID:
22354538
5.

Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells.

Chen YJ, Huang WC, Wei YL, Hsu SC, Yuan P, Lin HY, Wistuba II, Lee JJ, Yen CJ, Su WC, Chang KY, Chang WC, Chou TC, Chou CK, Tsai CH, Hung MC.

PLoS One. 2011;6(6):e21428. doi: 10.1371/journal.pone.0021428. Epub 2011 Jun 23.

6.

Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells.

Huang WC, Chen YJ, Li LY, Wei YL, Hsu SC, Tsai SL, Chiu PC, Huang WP, Wang YN, Chen CH, Chang WC, Chang WC, Chen AJ, Tsai CH, Hung MC.

J Biol Chem. 2011 Jun 10;286(23):20558-68. doi: 10.1074/jbc.M111.240796. Epub 2011 Apr 12.

7.

Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.

Galetti M, Petronini PG, Fumarola C, Cretella D, La Monica S, Bonelli M, Cavazzoni A, Saccani F, Caffarra C, Andreoli R, Mutti A, Tiseo M, Ardizzoni A, Alfieri RR.

PLoS One. 2015 Nov 4;10(11):e0141795. doi: 10.1371/journal.pone.0141795. eCollection 2015.

8.

Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.

Hegedüs C, Truta-Feles K, Antalffy G, Várady G, Német K, Ozvegy-Laczka C, Kéri G, Orfi L, Szakács G, Settleman J, Váradi A, Sarkadi B.

Biochem Pharmacol. 2012 Aug 1;84(3):260-7. doi: 10.1016/j.bcp.2012.04.010. Epub 2012 Apr 21.

PMID:
22548830
9.

The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.

Shi Z, Parmar S, Peng XX, Shen T, Robey RW, Bates SE, Fu LW, Shao Y, Chen YM, Zang F, Chen ZS.

Oncol Rep. 2009 Feb;21(2):483-9.

10.
11.

Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.

Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, Bates SE, Hidalgo M, Baker SD.

Cancer Biol Ther. 2007 Mar;6(3):432-8. Epub 2007 Mar 29.

PMID:
17312388
12.

AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.

Zhang H, Wang YJ, Zhang YK, Wang DS, Kathawala RJ, Patel A, Talele TT, Chen ZS, Fu LW.

Cancer Lett. 2014 Aug 1;350(1-2):61-8. doi: 10.1016/j.canlet.2014.04.008. Epub 2014 Apr 18.

PMID:
24747122
13.

Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.

Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW.

Cancer Lett. 2009 Jun 28;279(1):74-83. doi: 10.1016/j.canlet.2009.01.027. Epub 2009 Feb 18.

PMID:
19232821
14.

Downregulated ABCG2 enhances sensitivity to topoisomerase I inhibitor in epidermal growth factor receptor tyrosine kinase inhibitor-resistant non-small cell lung cancer.

Ohtsuka K, Ohnishi H, Morii T, Fujiwara M, Kishino T, Ogura W, Chiba M, Matsushima S, Goya T, Watanabe T.

J Thorac Oncol. 2010 Nov;5(11):1726-33. doi: 10.1097/JTO.0b013e3181f0b6af.

15.

ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells.

Ciardiello F, Caputo R, Borriello G, Del Bufalo D, Biroccio A, Zupi G, Bianco AR, Tortora G.

Int J Cancer. 2002 Mar 20;98(3):463-9.

16.
17.

BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.

Nagashima S, Soda H, Oka M, Kitazaki T, Shiozawa K, Nakamura Y, Takemura M, Yabuuchi H, Fukuda M, Tsukamoto K, Kohno S.

Cancer Chemother Pharmacol. 2006 Nov;58(5):594-600. Epub 2006 Mar 7.

PMID:
16520985
18.

Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.

Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR Jr, Fu LW, Ambudkar SV, Chen ZS.

Cancer Res. 2007 Nov 15;67(22):11012-20.

19.

Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.

Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y.

Cancer Sci. 2009 Sep;100(9):1701-7. doi: 10.1111/j.1349-7006.2009.01213.x. Epub 2009 May 12.

20.

Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells.

Liu H, Cheng D, Weichel AK, Osipo C, Wing LK, Chen B, Louis TE, Jordan VC.

Int J Oncol. 2006 Nov;29(5):1237-46.

PMID:
17016657

Supplemental Content

Support Center